Fig. 6

Reduced integrin expression in kidney ILC2s via TLR7/9. A Experimental protocol for in vivo TLR7 agonist treatment of IL-33-treated mice. Representative histograms (B) and frequencies (C) of integrin α4-, β7-, αv-, and β1-expressing ILC2s in IL-33-treated mice exposed to IMQ (n = 8). D Frequency of ILC2s in recombinant IL-33-treated mice exposed to IMQ (n = 8). E Experimental design for blocking integrin β7 in recombinant IL-33-treated old MRL-lpr (17 weeks old) mice. F Representative flow cytometry plot of ILCs and their frequencies after blocking integrin β7 in recombinant IL-33-treated old lpr mice (n = 6–9). G Graphical scheme of Itga4 MO-mediated downregulation of gene expression. H Expression (MFI) of integrin α4 and β7 after Itga4 MO transfection of kidney ILC2s (n = 5). I Expression (MFI) of CD127, ST2, and CD25 after Itga4 MO transfection of kidney ILC2s (n = 5). J Frequencies of AREG and TGF-β1 induced by Itga4 MO in kidney ILC2s (n = 5). All results are shown as the means ± SEMs, and the statistical analysis was performed using the Mann‒Whitney U test or Kruskal‒Wallis test. ns not significant; **P < 0.01; and ***P < 0.001